This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Abdelrahim M., Baker C.H., Abbruzzese J.L., Safe S.: Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006, 98, 855–868.AbdelrahimM.BakerC.H.AbbruzzeseJ.L.SafeS.Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradationJ Natl Cancer Inst20069885586810.1093/jnci/djj232Search in Google Scholar
Basha R., Ingersoll S.B., Sankpal U.T., Ahmad S., Baker C.H., Edwards J.R., Holloway R.W., Kaja S., Abdelrahim M.: Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 2011, 122, 163–170.BashaR.IngersollS.B.SankpalU.T.AhmadS.BakerC.H.EdwardsJ.R.HollowayR.W.KajaS.AbdelrahimM.Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factorsGynecol Oncol201112216317010.1016/j.ygyno.2011.03.014Search in Google Scholar
Chen W.S., Wei S.J., Liu J.M., Hsiao M., Kou-Lin J., Yang W.K.: Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001, 91, 894–899.ChenW.S.WeiS.J.LiuJ.M.HsiaoM.Kou-LinJ.YangW.K.Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolacInt J Cancer20019189489910.1002/1097-0215(200102)9999:9999<894::AID-IJC1146>3.0.CO;2-#Search in Google Scholar
Choi E.S., Shim J.H., Jung J.Y., Kim H.J., Choi K.H., Shin J.A., Nam J.S., Cho N.P., Cho S.D.: Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer Sci 2011, 102, 742–748.ChoiE.S.ShimJ.H.JungJ.Y.KimH.J.ChoiK.H.ShinJ.A.NamJ.S.ChoN.P.ChoS.D.Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1Cancer Sci201110274274810.1111/j.1349-7006.2011.01871.xSearch in Google Scholar
Colon J., Basha M.R., Madero-Visbal R., Konduri S., Baker C.H., Herrera L.J., Safe S., Sheikh-Hamad D., Abudayyeh A., Alvarado B., Abdelrahim M.: Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 2011, 29, 41–51.ColonJ.BashaM.R.Madero-VisbalR.KonduriS.BakerC.H.HerreraL.J.SafeS.Sheikh-HamadD.AbudayyehA.AlvaradoB.AbdelrahimM.Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic miceInvest New Drugs201129415110.1007/s10637-009-9331-8Search in Google Scholar
Eslin D., Sankpal U.T., Lee C., Sutphin R.M., Maliakal P., Currier E., Sholler G., Khan M., Basha R.: Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastoma. Mol Carcinog 2013, 52, 377–386.EslinD.SankpalU.T.LeeC.SutphinR.M.MaliakalP.CurrierE.ShollerG.KhanM.BashaR.Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastomaMol Carcinog20135237738610.1002/mc.21866Search in Google Scholar
Grandemange E., Fournel S., Boisramé B.: Field evaluation of the efficacy of tolfenamic acid administered in one single preoperative injection for the prevention of postoperative pain in the dog. J Vet Pharmacol Ther 2007, 30, 503–507.GrandemangeE.FournelS.BoisraméB.Field evaluation of the efficacy of tolfenamic acid administered in one single preoperative injection for the prevention of postoperative pain in the dogJ Vet Pharmacol Ther20073050350710.1111/j.1365-2885.2007.00899.xSearch in Google Scholar
Hillers K.R., Dernell W.S., Lafferty M.H., Withrow S.J., Lana S.E.: Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986–2003). J Am Vet Med Assoc 2005, 226, 1364–1367.HillersK.R.DernellW.S.LaffertyM.H.WithrowS.J.LanaS.E.Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986–2003)J Am Vet Med Assoc20052261364136710.2460/javma.2005.226.1364Search in Google Scholar
Khwaja F.S., Quann E.J., Pattabiraman N., Wynne S., Djakiew D.: Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Mol Cancer Ther 2008, 7, 3539–3545.KhwajaF.S.QuannE.J.PattabiramanN.WynneS.DjakiewD.Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cellsMol Cancer Ther200873539354510.1158/1535-7163.MCT-08-0512Search in Google Scholar
McKellar Q.A., Lees P., Gettinby G.: Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol 1994, 253, 191–200.McKellarQ.A.LeesP.GettinbyG.Pharmacodynamics of tolfenamic acid in dogsEvaluation of dose response relationships. Eur J Pharmacol199425319120010.1016/0014-2999(94)90191-0Search in Google Scholar
Mullins M.N., Lana S.E., Dernell W.S., Ogilvie G.K., Withrow S.J., Ehrhart E.J.: Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Intern Med 2004, 18, 859–865.MullinsM.N.LanaS.E.DernellW.S.OgilvieG.K.WithrowS.J.EhrhartE.J.Cyclooxygenase-2 expression in canine appendicular osteosarcomasJ Vet Intern Med20041885986510.1111/j.1939-1676.2004.tb02633.xSearch in Google Scholar
Okamoto A., Shirakawa T., Bito T., Shigemura K., Hamada K., Gotoh A., Fujisawa M., Kawabata M.: Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo Urology 2008, 71, 156–160.OkamotoA.ShirakawaT.BitoT.ShigemuraK.HamadaK.GotohA.FujisawaM.KawabataM.Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivoUrology20087115616010.1016/j.urology.2007.09.061Search in Google Scholar
Pang L.Y., Argyle S.A., Kamida A., Morrison K.O., Argyle D.J.: The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro BMC Vet Res 2016, 10, 184.PangL.Y.ArgyleS.A.KamidaA.MorrisonK.O.ArgyleD.J.The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitroBMC Vet Res20161018410.1186/PREACCEPT-9511370941246208Search in Google Scholar
Papineni S., Chintharlapalli S., Abdelrahim M., Lee S.O., Burghardt R., Abudayyeh A., Baker C., Herrera L., Safe S.: Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009, 30, 1193–1201.PapineniS.ChintharlapalliS.AbdelrahimM.LeeS.O.BurghardtR.AbudayyehA.BakerC.HerreraL.SafeS.Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-MetCarcinogenesis2009301193120110.1093/carcin/bgp092Search in Google Scholar
Rosenberger J.A., Pablo N.V., Crawford P.C.: Prevalence of and intrinsic risk factors for appendicular osteosarcoma in dogs: 179 cases (1996–2005). J Am Vet Med Assoc 2007, 231, 1076–1080.RosenbergerJ.A.PabloN.V.CrawfordP.C.Prevalence of and intrinsic risk factors for appendicular osteosarcoma in dogs: 179 cases (1996–2005)J Am Vet Med Assoc20072311076108010.2460/javma.231.7.1076Search in Google Scholar
Roze M., Thomas E., Davot J.L.: Tolfenamic acid in the control of ocular inflammation in the dog: pharmacokinetics, and clinical results obtained in an experimental model. J Small Anim Pract 1996, 37, 371–375.RozeM.ThomasE.DavotJ.L.Tolfenamic acid in the control of ocular inflammation in the dog: pharmacokinetics, and clinical results obtained in an experimental modelJ Small Anim Pract19963737137510.1111/j.1748-5827.1996.tb02418.xSearch in Google Scholar
Ru G., Terracini B., Glickman L.T.: Host related risk factors for canine osteosarcoma. Vet J 1998, 156, 31–39.RuG.TerraciniB.GlickmanL.T.Host related risk factors for canine osteosarcomaVet J1998156313910.1016/S1090-0233(98)80059-2Search in Google Scholar
Shigemura K., Shirakawa T., Wada Y., Kamidono S., Fujisawa M., Gotoh A.: Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo Urology 2005, 66, 1239–1244.ShigemuraK.ShirakawaT.WadaY.KamidonoS.FujisawaM.GotohA.Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivoUrology2005661239124410.1016/j.urology.2005.06.07616360450Search in Google Scholar
Spodnick G.J., Berg J., Rand W.M., Schelling S.H., Couto G., Harvey H.J., Henderson R.A., MacEwen G., Mauldin N., McCaw D.L.: Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J Am Vet Med Assoc 1992, 200, 995–999.SpodnickG.J.BergJ.RandW.M.SchellingS.H.CoutoG.HarveyH.J.HendersonR.A.MacEwenG.MauldinN.McCawD.L.Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988)J Am Vet Med Assoc1992200995999Search in Google Scholar
Wilson H., Chadalapaka G., Jutooru I., Sheppard S., Pfent C., Safe S.: Effect of tolfenamic acid on canine cancer cell proliferation, specificity protein (Sp) transcription factors, and Sp-regulated proteins in canine osteosarcoma, mammary carcinoma, and melanoma cells. J Vet Intern Med 2012, 26, 977–986.WilsonH.ChadalapakaG.JutooruI.SheppardS.PfentC.SafeS.Effect of tolfenamic acid on canine cancer cell proliferation, specificity protein (Sp) transcription factors, and Sp-regulated proteins in canine osteosarcoma, mammary carcinoma, and melanoma cellsJ Vet Intern Med20122697798610.1111/j.1939-1676.2012.00931.x490653622536857Search in Google Scholar
Withrow S.J., Vail M.D.: Withrow and MacEwen’s Small Animal Clinical Oncology, edited by S.J. Withrow, D.M. Vail, W.B. Saunders, St. Louis, 2007, p. 71.WithrowS.J.VailM.D.Withrow and MacEwen’s Small Animal Clinical Oncologyedited byWithrowS.J.VailD.M.SaundersW.B.St. Louis2007p7110.1016/B978-072160558-6.50013-7Search in Google Scholar